Zacks Investment Research upgraded shares of ZIOPHARM Oncology (NASDAQ:ZIOP) from a hold rating to a buy rating in a research report report published on Saturday. Zacks Investment Research currently has $5.00 price objective on the biotechnology company’s stock.
According to Zacks, “ZIOPHARM Oncology, Inc. is a biopharmaceutical company engaged in the development and commercialization of a diverse, risk-sensitive portfolio of in-licensed cancer drugs to address unmet medical needs. The Company applies new insights from molecular and cancer biology to understand the efficacy and safety limitations of approved and developmental cancer therapies and identifies proprietary and related molecules for better patient treatment. “
Other research analysts also recently issued reports about the stock. HC Wainwright reissued a buy rating and set a $9.50 price target on shares of ZIOPHARM Oncology in a research note on Tuesday, November 7th. Raymond James Financial reissued a hold rating on shares of ZIOPHARM Oncology in a research note on Monday, December 11th. ValuEngine downgraded shares of ZIOPHARM Oncology from a hold rating to a sell rating in a research note on Friday, September 15th. Finally, BidaskClub raised shares of ZIOPHARM Oncology from a strong sell rating to a sell rating in a research note on Thursday, January 4th. Two equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and three have issued a buy rating to the company. The stock presently has an average rating of Hold and an average price target of $12.67.
ZIOPHARM Oncology (NASDAQ:ZIOP) last announced its earnings results on Monday, November 6th. The biotechnology company reported ($0.13) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.13). The company had revenue of $1.60 million during the quarter, compared to analysts’ expectations of $1.66 million. The company’s revenue for the quarter was up .0% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.11) earnings per share. analysts predict that ZIOPHARM Oncology will post -0.54 EPS for the current fiscal year.
In other ZIOPHARM Oncology news, CEO Laurence James Neil Cooper purchased 6,440 shares of the firm’s stock in a transaction on Wednesday, November 8th. The shares were purchased at an average cost of $4.68 per share, with a total value of $30,139.20. Following the completion of the purchase, the chief executive officer now owns 1,083,731 shares of the company’s stock, valued at approximately $5,071,861.08. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this link. Company insiders own 10.40% of the company’s stock.
Several institutional investors have recently modified their holdings of the company. Principal Financial Group Inc. grew its holdings in shares of ZIOPHARM Oncology by 7.5% in the second quarter. Principal Financial Group Inc. now owns 24,046 shares of the biotechnology company’s stock worth $150,000 after purchasing an additional 1,673 shares during the last quarter. Amalgamated Bank grew its holdings in shares of ZIOPHARM Oncology by 12.9% in the second quarter. Amalgamated Bank now owns 16,807 shares of the biotechnology company’s stock worth $105,000 after purchasing an additional 1,924 shares during the last quarter. Nationwide Fund Advisors grew its holdings in shares of ZIOPHARM Oncology by 3.0% in the second quarter. Nationwide Fund Advisors now owns 72,799 shares of the biotechnology company’s stock worth $453,000 after purchasing an additional 2,127 shares during the last quarter. Legal & General Group Plc grew its holdings in shares of ZIOPHARM Oncology by 6.3% in the second quarter. Legal & General Group Plc now owns 44,655 shares of the biotechnology company’s stock worth $279,000 after purchasing an additional 2,666 shares during the last quarter. Finally, Private Advisor Group LLC grew its holdings in shares of ZIOPHARM Oncology by 10.6% in the second quarter. Private Advisor Group LLC now owns 45,949 shares of the biotechnology company’s stock worth $271,000 after purchasing an additional 4,408 shares during the last quarter. Hedge funds and other institutional investors own 40.23% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “ZIOPHARM Oncology (ZIOP) Rating Increased to Buy at Zacks Investment Research” was originally posted by Community Financial News and is the property of of Community Financial News. If you are reading this article on another domain, it was illegally copied and republished in violation of United States and international copyright law. The legal version of this article can be accessed at https://www.com-unik.info/2018/01/09/ziopharm-oncology-ziop-rating-increased-to-buy-at-zacks-investment-research.html.
ZIOPHARM Oncology Company Profile
ZIOPHARM Oncology, Inc is a biopharmaceutical company, which is seeking to develop, acquire and commercialize, on its own or with partners, a portfolio of cancer therapies that address unmet medical needs. The Company is focused on developing products in immuno-oncology that employ gene expression, control and cell technologies to deliver cell- and viral-based therapies for the treatment of cancer and graft-versus-host-disease.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ZIOPHARM Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZIOPHARM Oncology and related companies with MarketBeat.com's FREE daily email newsletter.